Aprovel is an angiotensin II receptor antagonist, used at elevated blood pressure.
Release form and composition
Make Aprovel tablets containing the active substance irbesartan in an amount of 0.15 or 0.3 g.
Auxiliary components of the drug are: corn starch, lactose monohydrate, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, croscarmellose sodium, pregelatinized corn starch, poloxamer 188.
In blister packs of 14 tablets.
Indications for use
According to the instructions, Aprovel is indicated for essential arterial hypertension.
As part of the combined treatment, Aprovel is prescribed for nephropathy in patients with arterial hypertension and type 2 diabetes.
According to the instructions, Aprovel is contraindicated in:
- Pregnancy and breastfeeding;
- Hypersensitivity to irbesartan or auxiliary components of the drug;
- Under the age of 18;
- Hereditary intolerance to galactose, impaired absorption of galactose or glucose, lack of lactase.
In the application of Aprovel, caution should be exercised when:
- Hypertrophic obstructive cardiomyopathy;
- Stenosis of the aortic or mitral valve;
- Observe low-salt diet;
- Bilateral stenosis of the renal arteries or unilateral stenosis of the artery of a single kidney;
- Severe liver failure;
- After kidney transplantation;
- Chronic heart failure III-IV functional class NYHA classification;
- Diuretic treatment;
- Renal failure;
- Atherosclerosis of cerebral vessels, ischemic heart disease.
Dosing and Administration
According to the instructions, Aprovel take inside entirely, drinking water. The medication is taken regardless of the meal.
The initial and maintenance dosage is 0.15 g per day, which ensures optimal control of blood pressure. If the patient is on hemodialysis, or has advanced age, the drug is prescribed in the initial dose of 0.075 g per day.
If 0.15 g of the drug does not deliver the desired therapeutic effect, it is advisable to increase the dosage to 0.3 g per day or consult a doctor for the purpose of prescribing an alternative antihypertensive agent.
Patients with arterial hypertension and type 2 diabetes mellitus Aprovel are prescribed at an initial dose of 0.15 g per day, gradually increasing it to 0.3 g per day (the optimal dose for nephropathy therapy).
If the patient's water-electrolyte balance is impaired, it is recommended to eliminate hyponatremia and BCC before starting Aprovel.
In case of impaired renal function, liver, mild or moderate severity of dose adjustment of Aprovel is not required.
It is necessary to carefully observe the dosage of Aprovel, as it can cause the following symptoms of overdose:
- A pronounced decrease in blood pressure;
If symptoms of overdose appear, it is recommended to do a gastric lavage, take adsorbents and carry out symptomatic treatment.
The use of Aprovel can cause the following adverse reactions:
- Central nervous system: dizziness, headache;
- Respiratory system: cough;
- Cardiovascular system: skin hyperemia, tachycardia;
- Sexual system: sexual dysfunction;
- The digestive system: vomiting, diarrhea, dyspepsia, heartburn, abnormal liver function, hepatitis;
- Laboratory indicators: hyperkalemia, clinically insignificant decrease in hemoglobin level;
- Allergic reactions: skin rash, urticaria, angioedema;
- Musculoskeletal system: arthralgia, myalgia, convulsions;
- Others: chest pain, fatigue, tinnitus.
When hyponatremia, dehydration, in patients on hemodialysis, Aprovel can cause clinically significant arterial hypotension, especially after taking the first dose of medication. With these pathological conditions, it is necessary to adjust the dosage of the drug.
Patients with renal artery stenosis who take medications that affect the RAAS are at risk of developing severe arterial hypotension or renal failure.
In case of renal failure, patients should be monitored for serum creatinine and potassium during the aprovel use period.
Aprovel slows down the progression of cardiovascular and renal lesions when it is used in diabetes and hypertension, accompanied by kidney damage.
Patients with heart disease and renal failure have a high risk of developing hyperkalemia as a result of the use of irbesartan. Therefore, this category of patients should be prescribed medication with caution.
Care should also be taken in appointing Aprovel to patients with mitral or aortic stenosis, or in the presence of obstructive hypertrophic cardiomyopathy.
Aprovel is ineffective against patients with primary aldosteronism.
According to the instructions, Aprovel does not affect the patient's ability to drive a vehicle and other mechanisms that require increased concentration of attention.
The following drugs are analogues of Aprovel:
In case of replacing Aprovel with a similar drug, it is recommended to consult with your doctor first.
Terms and conditions of storage
Aprovel refers to the list of drugs B. Keep it should be in a dry, dark place inaccessible to children. Shelf life - 3 years.